Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer

NCT07106892 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer (CRC)

Interventions

DRUG: HLX43 Dose 1;
DRUG: HLX43 Dose 2;
DRUG: HLX43 Dose 3;

Sponsor

Shanghai Henlius Biotech